PI-103 is a small molecule drug developed by the pharmaceutical company Piramed Ltd. It is a potent inhibitor of phosphoinositide 3-kinase (PI3K), a class of enzymes that play a critical role in the regulation of cell growth and survival. PI-103 is currently being studied as a potential treatment for various types of cancer.
Chemical name: The chemical name of PI-103 is 2-(4-Morpholinyl)-8-phenyl-4H-1-benzopyran-4-one.
Molecular formula: The molecular formula for PI-103 is C20H19NO3.
Formula weight: The formula weight for PI-103 is 321.37 g/mol.
CAS No: The CAS number for PI-103 is 371935-74-9.
Top Ten Keywords and Synonyms:
Synonyms: PI103; PI 103; 2-(4-Morpholinyl)-8-phenyl-4H-1-benzopyran-4-one; Piramed Compound 10
Health Benefits of PI-103: PI-103 is designed to inhibit the activity of PI3K, which is known to be overactive in many types of cancer cells. By inhibiting PI3K, PI-103 may help to slow or stop the growth of cancer cells, potentially leading to tumor regression and improved patient outcomes.
Potential Effects of PI-103: Preclinical studies have shown that PI-103 can inhibit the growth of various types of cancer cells, including breast, lung, and prostate cancer cells. Additionally, PI-103 has been shown to induce apoptosis (cell death) and autophagy (a process by which cells degrade and recycle their own components) in cancer cells.
Product Mechanism: PI-103 works by targeting and inhibiting the activity of PI3K, an enzyme that plays a key role in the regulation of cell growth and survival. The inhibition of PI3K by PI-103 leads to reduced activation of downstream signaling pathways, including the AKT pathway, which is known to promote cell growth and survival. This results in decreased cancer cell proliferation and increased sensitivity to chemotherapy and radiation therapy.
Safety: As with any new drug, the safety of PI-103 is being carefully evaluated in clinical trials. Preliminary studies suggest that PI-103 is generally well-tolerated, with manageable side effects.
Side Effects: Common side effects of PI-103 include fatigue, nausea, vomiting, and diarrhea. Less common but more serious side effects may include low white blood cell count, liver damage, and heart problems.
Dosing Information: The appropriate dose of PI-103 depends on several factors, including the patient's age, weight, and overall health status. Dosage and duration of treatment are determined by the treating physician.
Conclusion: PI-103 is a promising new drug under investigation for the treatment of various types of cancer. By inhibiting the activity of PI3K, it has the potential to slow or stop the growth of tumors, potentially improving patient outcomes. While the drug is still in clinical trials, preliminary studies suggest that it is generally well-tolerated with manageable side effects. As research continues, PI-103 may represent an exciting new option for patients with cancer.
